>brush up on your understanding of RSS. This will help you fully appreciate and fully understand the issues involved.
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
>
I am glad this conversation is happening now as it needs to be made clear what fair use of RSS feeds actually means. There may
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
be webmasters who are republishing RSS feeds in all innocence at the moment not realising the furore that is going on around them
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
with regards to their republishing activities. I would like to help clear up any misunderstandings that surround RSS republishi
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
g.
Being an RSS publisher myself who is considering republishing other authors RSS feeds I would like to make sure I a
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ketingstudies.net/">Rok Hrastnik has enthused.
If you wish to republish an RSS feed then you should first consult
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
the publisher with your intentions. This would be an email to the author stating how you wish to reuse their feed and the page or
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
pages the feed will be republished on and the attributions you will make. You will need to clarify some points. If the authors f
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
ed contains ads then will they be republished? Will you be monetizing the authors work by placing ads on your republished page? T
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
o avoid conflict these issues need to be sorted out.
The general guidelines Rok Hrastrnik has provided state that the
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
rticle title must link back to the original article. If the RSS feeds contains a complete article only an excerpt, Rok suggests 1
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
0 to 200 words, can be republished. A link should be provided to the article source, the website of the original publisher.
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Further to this it is suggested that no archives are kept on the republished site and no full articles are used. I would su
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
gest permission is sought from the original author if you wish to keep an archive on your site.
You can follow this d
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de